Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 13/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.33 |
| ▸ | KDR | P35968 | 2/20 | 0.33 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.33 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9256107 | 0.94 | SIGMAR1 (0.40) | SIGMAR1CHRNB2CHRNA4NAMPTSLC22A12 | |
| SCHEMBL9256028 | 0.85 | NAMPT (0.36) | SIGMAR1NAMPTTIPARP | |
| SCHEMBL9261349 | 0.82 | NAMPT (0.36) | SIGMAR1NAMPTTIPARP | |
| SCHEMBL9252057 | 0.81 | MAOA (0.46) | — | |
| SCHEMBL9257457 | 0.75 | DPP8 (0.39) | NAMPTTIPARP | |
| SCHEMBL9257345 | 0.74 | FFAR4 (0.33) | SIGMAR1NAMPT | |
| SCHEMBL9261326 | 0.74 | FFAR4 (0.33) | SIGMAR1NAMPT | |
| SCHEMBL9256079 | 0.73 | DPP8 (0.40) | NAMPTTIPARP | |
| SCHEMBL8371340 | 0.70 | SIGMAR1 (0.46) | SIGMAR1CHRNB2CHRNA4NAMPTPDGFRB | |
| SCHEMBL30133729 | 0.70 | SIGMAR1 (0.46) | SIGMAR1CHRNB2CHRNA4NAMPTPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120135997-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A LACTAM OR BENZENESULFONAMIDE COMPOUND | SHIONOGI & CO., LTD. (JP) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135997-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A LACTAM OR BENZENESULFONAMIDE COMPOUND | BACE1, STS, APP | SIGMAR1 1154/4885CHRNB2 2171/4885CHRNA4 2231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.